Govind Kulkarni
M.D (Med) Cardiology Fellow ( Sydney) Consulting Physicians, Diabetologist & Cardiologis
Title: FOURIER STUDY for new lipid lowering injectable drug PCSK9 INHIBITORS.
Biography
Biography: Govind Kulkarni
Abstract
PCSK9 INHIBITORS
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene in humans on chromosome 1. PCSK9 is ubiquitously expressed in many tissues and cell types.PCSK9 binds to the receptor for low-density lipoprotein particles (LDL), which typically transport 3,000 to 6,000 fat molecules (including cholesterol) per particle, within extracellular fluid. The LDL receptor (LDLR), on liver and other cell membranes, binds and initiates ingestion of LDL-particles from extracellular fluid into cells, thus reducing LDL particle concentrations. If PCSK9 is blocked, more LDLRs are recycled and are present on the surface of cells to remove LDL-particles from the extracellular fluid. Therefore, blocking PCSK9 can lower blood LDL-particle concentrations.